We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

125 hedge funds and large institutions have $2.08B invested in Verve Therapeutics in 2022 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 55 increasing their positions, 16 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more call options, than puts

Call options by funds: $16M | Put options by funds: $4.26M

244% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 16

199% more capital invested

Capital invested by funds: $696M → $2.08B (+$1.39B)

114% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 21

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

24% more funds holding

Funds holding: 101 → 125 (+24)

7.61% more ownership

Funds ownership: 93.65% → 101.26% (+7.6%)

Holders
125
Holders Change
+24
Holders Change %
+23.76%
% of All Funds
2.15%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
45
Increased
55
Reduced
16
Closed
21
Calls
$16M
Puts
$4.26M
Net Calls
+$11.7M
Net Calls Change
+$8.05M

Top Buyers

1
State Street
State Street
Massachusetts
+$70M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$69.1M
3
AIM
ARK Investment Management
Florida
+$43.4M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$42M
5
APM
Avidity Partners Management
Texas
+$33.3M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$32.3M
2
AVM
Arch Venture Management
Illinois
-$16M
3
Millennium Management
Millennium Management
New York
-$11.9M
4
RG
Redmile Group
California
-$10.5M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$8.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
AI
1
Alphabet Inc
California
$377M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$257M +$69.1M +2,166,571 +41%
Vanguard Group
3
Vanguard Group
Pennsylvania
$126M +$42M +1,316,619 +56%
AIM
4
ARK Investment Management
Florida
$117M +$43.4M +1,359,735 +67%
BlackRock
5
BlackRock
New York
$116M +$25.3M +792,139 +31%
CC
6
Casdin Capital
New York
$109M +$1.28M +40,000 +1%
State Street
7
State Street
Massachusetts
$96.2M +$70M +2,194,551 +363%
AVM
8
Arch Venture Management
Illinois
$69M -$16M -500,000 -20%
JP Morgan Chase
9
JP Morgan Chase
New York
$65.9M +$18M +563,852 +42%
Federated Hermes
10
Federated Hermes
Pennsylvania
$60.1M +$20.8M +651,900 +59%
RG
11
Redmile Group
California
$51.7M -$10.5M -328,421 -18%
BBA
12
Baker Bros. Advisors
New York
$48.7M – – –
T. Rowe Price Investment Management
13
T. Rowe Price Investment Management
Maryland
$43.1M +$40M +1,254,816 New
PHS
14
PFM Health Sciences
California
$40.1M +$10.3M +323,622 +38%
APM
15
Avidity Partners Management
Texas
$35.8M +$33.3M +1,042,706 New
Wellington Management Group
16
Wellington Management Group
Massachusetts
$34.7M -$8.06M -252,676 -20%
NHAS
17
Novo Holdings A/S
Denmark
$31.3M -$510K -15,989 -2%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$26.9M +$10.1M +315,492 +68%
Sumitomo Mitsui Trust Group
19
Sumitomo Mitsui Trust Group
Japan
$26.6M +$21.1M +660,465 +573%
DTC
20
Deep Track Capital
Connecticut
$26.6M +$24.7M +775,000 New
DM
21
Deerfield Management
New York
$25.8M +$23.9M +750,000 New
NAMA
22
Nikko Asset Management Americas
New York
$24.4M +$21.1M +660,465 +573%
BI
23
BVF Inc
California
$22.3M +$20.7M +650,000 New
MB
24
MPM BioImpact
Massachusetts
$21.8M +$20.3M +635,792 New
CAM
25
Cormorant Asset Management
Massachusetts
$20.6M -$3.21M -100,710 -14%
1
2 3 4 5

VERV Hedge Fund Activity: Q3 2022 in Review

125 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2022, worth a combined $2.08B — up 199% from $696M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new VERV positions and 21 closed out — a net gain of 24 holders — while 55 added to existing stakes and 16 trimmed.

The largest buyer was State Street, adding an estimated $70M. The largest seller was Citadel Advisors, cutting an estimated $32.3M.

  • 125 institutional investors held Verve Therapeutics (VERV) as of Q3 2022, up from 101 in Q2 2022.
  • Funds reported $2.08B of Verve Therapeutics stock for Q3 2022, up 199% quarter-over-quarter.
  • 45 funds opened new Verve Therapeutics positions in Q3 2022 and 21 closed out, a net change of +24 holders.
  • The largest Verve Therapeutics buyer in Q3 2022 was State Street, an estimated $70M added.
  • The largest Verve Therapeutics seller in Q3 2022 was Citadel Advisors, an estimated $32.3M sold.

Based on aggregated 13F filings for Q3 2022.